Navigation Links
Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Date:6/8/2009

VANCOUVER, June 8 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, for use in both permanent and retrievable indications. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as previously announced in March 2008.

The Option IVC Filter is used for the prevention of recurrent pulmonary embolism (PE). The device is implanted, typically by interventional radiologists in a minimally invasive procedure, into the body's inferior vena cava to prevent PE. Option is specifically designed for use as both a permanent or temporary implant (in temporary, or retrievable, indications, a physician may later perform a second surgical procedure to remove the Option IVC Filter if necessary or where mandated clinically).

"This important FDA clearance of the Option IVC Filter continues Angiotech's mission of offering the most highly innovative technology solutions to our physician customers and their patients," said Dr. William Hunter, President and CEO of Angiotech. "We are excited to commence commercial sales of Option through our dedicated Interventional Sales Team in the very near future. We believe the flexibility to use the Option IVC Filter in both permanent and retrievable indications, with clinical study data indicating 92% retrieval success, and a retrieval at up to 175 days post-implantation, provides Option the opportunity to be the market leading product in PE prevention."

According to market analysis conducted by Millennium Research Group, the U.S. market for IVC filters was approximately $200 million in 2007 (with approxima
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Angiotech Enters License, Distribution and Supply Agreements for Fibrin and Thrombin Technologies with Haemacure Corporation
2. Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system
3. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
4. Angiotech launches e-commerce website that allows customers to order Quill(TM) SRS product line
5. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
6. Angiotech announces date of annual general meeting of shareholders
7. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
8. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
9. Angiotech announces positive results from Bio-Seal(TM) clinical study
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
11. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014 Mathematic studies at the ... , and funded by the Jeffrey Epstein VI Foundation ... can be visually identified for elimination. These aggressive cells are ... which shows a topological map of what to look for ... research, for while tumor cells can be extracted from biopsy, ...
(Date:8/21/2014)... 21, 2014 Pursuit Solutions ( ... technology and services for Life Sciences sales and ... Use of New Commercial Sales Models” by Peter ... , The article examines some innovative models used ... being tested in the pharmaceutical market. Robinson grades ...
(Date:8/21/2014)... On Wednesday of last week RENU 28, the world's ... became available for purchase in Australia and New Zealand, and ... 28 works is, if you think about the definition of ... cellular renewal within your body. If you think about the ... cellular renewal. What RENU 28 does is it works with ...
(Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
Breaking Biology Technology:Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2RENU 28 Skin Care Now Available in Australia and New Zealand 2Seeing a molecule breathe 2
... VEENENDAAL, The Netherlands, June 2 ... today announced the creation,of an exclusive partnership and ... for an undisclosed sum. The two companies, headquartered ... the combination,will strengthen Nucletron,s position as global leader ...
... The American Institute of Aeronautics and Astronautics ... top emerging aerospace technologies. Developed by AIAA,s ... following: 1. "Greener Aviation" Technologies including emission ... the Federal Aviation Administration,s Continuous Low Emissions, Energy ...
... First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL , ... to treat Analysis results per FDA agreed upon Statistical Analysis Plan , ... Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021 ... Rate 37.1% vs. 14.3%; p=0.003 , ...
Cached Biology Technology:Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 3AIAA names top ten emerging aerospace technologies of 2009 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 3Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 4Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 5
(Date:8/21/2014)... use a previously unknown process for harvesting energy and ... a Penn State University scientist has discovered. The discovery ... plant growth, harvesting energy from the Sun, and understanding ... and other lakes worldwide. A paper describing the discovery ... edition of the journal Science on 21 ...
(Date:8/21/2014)... intake, health and quality of life of older adults ... the University of Waterloo receiving close to $1.5 million ... (CIHR). , Professor Heather Keller, of the Faculty ... research chair in nutrition and aging, will receive $979,000 ... in long-term care homes are poorly nourished. The project ...
(Date:8/21/2014)... consists of radiations in the 3.3 to 4.4 nanometre ... biological tissues. New theoretical findings show that it is ... These could be the basis of an optimal technique ... or to be used in high-precision spectroscopy. Now, a ... efficiently generate the harmonic radiationswhich are multiples of an ...
Breaking Biology News(10 mins):Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Grants will fund landmark aging research at Waterloo 2Water window imaging opportunity 2
... A drug made from the saliva of the Gila ... food. Researchers at the Sahlgrenska Academy, University of Gothenburg, ... ceased their cravings for both food and chocolate. ... diabetes are offered a pharmaceutical preparation called Exenatide, which ...
... 15, 2012) The Mass. Eye and Ear Curing Kids ... help the brain locate sound, identify genes that cause congenital ... for childhood eye cancer. The 2011/2012 Curing Kids Fund grants ... Sense-sation! gala. This year,s grant recipients are: , ...
... are used in gardens, burned for heat and energy, and ... grass family that includes corn, sorghum and sugarcane. Two new, ... (an ornamental that likely is a parent of Miscanthus ... sequencing the M. sinensis genome. The studies reveal ...
Cached Biology News:Drugs from lizard saliva reduces the cravings for food 2Mass. Eye and Ear announces Curing Kids Fund grant recipients 2Maps of Miscanthus genome offer insight into grass evolution 2Maps of Miscanthus genome offer insight into grass evolution 3
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
anti-dansyl, rabbit IgG fraction *1 mg/mL* Secondary Detection; Anti-Dye and Anti-Hapten Antibodies...
MOUSE ANTI GUINEA PIG T-CELLS (PAN):FITC Immunogen: Guinea pig peritoneal T-cells...
... (100+kb), fosmid (40kb), and large plasmid insert ... othe BAC vector. On command 20-50 fold ... recombinant DNA purification. Available with blue-white screening ... for the highest insert stability. Kits include ...
Biology Products: